http://wordpress.com/tag/pdgf/ Feed of posts on WordPress.com tagged "pdgf" Sat, 11 Oct 2008 17:22:56 +0000 http://wordpress.com/tags/ en http://kinasecentral.wordpress.com/?p=710 Thu, 09 Oct 2008 15:36:21 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/10/09/imatinib-shows-potential-in-pulmonary-arterial-hypertension-pah/ Phase II data presented at the European Respiratory Society show Imatinib to demonstrate efficacy in the treatment of pulmonary arterial hypertension (PAH). ]]> http://kinasecentral.wordpress.com/?p=450 Mon, 01 Sep 2008 15:00:08 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/09/01/gleevec-receives-priority-review-in-us-for-gist-after-surgery/ Gleevec (imatinib) has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST). ]]> http://kinasecentral.wordpress.com/?p=332 Tue, 05 Aug 2008 15:05:51 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/08/05/imatinib-in-connective-tissue-diseases/ Three papers in this months Arthritis and Rheumatism discuss Imatinib in connective tissue diseases:

• Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease
• Imatinib mesylate treatment of nephrogenic systemic fibrosis
• Is imatinib mesylate a promising drug in systemic sclerosis?

]]> http://kinasecentral.wordpress.com/?p=316 Mon, 04 Aug 2008 13:58:45 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/08/04/retrospective-study-shows-imatinib-treatment-induces-hypogammaglobulinemia/ A retrospective study of 72 chronic myeloid leukemia and 15 gastrointestinal stromal tumor patients has shown that patients developed a significant reduction of gammaglobulin and immunoglobulin serum levels.

]]> http://kinasecentral.wordpress.com/?p=264 Tue, 22 Jul 2008 15:53:02 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/07/22/kinase-domain-mutation-detection-indicates-risk-of-disease-progression/ Researchers from Imperial College London have published data showing that screening of patients for bcr-abl mutations following imatinib treatment can indicate a patient's risk of disease progression

]]> http://kinasecentral.wordpress.com/?p=223 Thu, 03 Jul 2008 01:59:40 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/07/02/amgens-motesanib-demonstrates-efficacy-in-thyroid-cancer/ Phase II data published in the NEJM show Amgen's Motesanib (AMG706) to induce partial responses in patients with advanced or metastatic differentiated thyroid cancer

]]> http://kinasecentral.wordpress.com/?p=202 Tue, 24 Jun 2008 22:56:30 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/24/resistance-to-imatinib-gleevec-caused-by-lyn-kinase/ Data published in this weeks Journal of the National Cancer Institute shows that activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML)

]]> http://kinasecentral.wordpress.com/?p=197 Tue, 24 Jun 2008 13:59:43 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/24/imatinib-increases-thrombolytic-therapeutic-windown-in-stroke/ Researchers from the University of Michigan and the Karolinska Institute have found that imatinib (Gleevec) extends the three-hour thrombolytic therapeutic window for ischemic stroke in a mouse model. The drug was found to reduce edema associated with ischemic stroke and improvethe response to tissue plasminogenactivator.

]]> http://kinasecentral.wordpress.com/?p=192 Thu, 19 Jun 2008 13:36:01 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/19/rhabdomyolysis-possible-adverse-effect-of-imatinib/ In a letter to the New England Journal of Medicine French doctors have reported a case of severerhabdomyolysis following treatment with Gleevec (imatinib). The patient was taking imatinib as part of a clinical trial for the treatment of aggressive fibromatosis.

]]> http://kinasecentral.wordpress.com/?p=170 Fri, 13 Jun 2008 15:49:04 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/13/high-initial-dose-of-gleevec-results-in-better-early-responses-in-cml/ New phase III data shows that when Gleevec is administered at a high initial dose (800 mg/day) there is a faster achievement of clinical milestones. The study did not however, meet its primary endpoint at 1 year

]]> http://kinasecentral.wordpress.com/?p=163 Wed, 11 Jun 2008 19:26:41 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/11/imatinib-modulates-synovial-fibroblasts-in-arthritis-model/ Data presented at EULAR shows that PDGFR kinase inhibitors can modulate synovial fibroblast activity in a mouse collagen induced arthritis (CIA) model. Drugs tested included imatinib mesylate (Gleevec) and SU9518

]]> http://kinasecentral.wordpress.com/?p=159 Wed, 11 Jun 2008 16:52:02 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/11/anti-fibrotic-effect-of-imatinib-does-not-appear-to-affect-vasculature/ Data presented at EULAR show Imatinib does not inhibit proliferation, migration or tube forming in endothelial cells, a possible concernt in its potential antifibrotic use for the treatment of systemic sclerosis

]]> http://kinasecentral.wordpress.com/?p=144 Thu, 05 Jun 2008 13:06:57 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/05/imatinib-in-c-kit-or-pdgfr-%ce%b2-expressing-metastatic-breast-cancer/ Imatinib mesylate was tested in patients with metastatic breast cancer expressing PDGFR or c-kit. No objective responses were observed and Imatinib given alone does not appear to demonstrate clinical activity

]]> http://kinasecentral.wordpress.com/?p=130 Mon, 02 Jun 2008 22:54:07 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/06/02/imatinib-in-chronic-myeloid-leukemia/ Researchers from Imperial College London have published data on long term (5 yr) treatment of Chronic Myeloid Leukemia (CML) patients with Imatinib. At 5 years estimated overall survival and PFS were 83.2% and 82.7%, respectively.

]]> http://kinasecentral.wordpress.com/?p=51 Tue, 13 May 2008 15:16:52 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/05/13/imatinib-enters-phase-ii-trial-for-nephrogenic-systemic-fibrosis/ Novartis have initiated a Phase 2 Pilot Study of Imatinib (Gleevec) for Nephrogenic Systemic Fibrosis

]]> http://kinasecentral.wordpress.com/?p=44 Sun, 11 May 2008 15:18:00 +0000 crimsoncanary http://kinasecentral.fr.wordpress.com/2008/05/11/kirins-kinase-inhibitor-ki-11502-shows-activity-against-pdgf/ In eosinophilic leukemia EOL-1 cells Ki11502 was found to decrease levels of p-PDGFR and its downstream signals, including p-Akt, p-ERK, and p-STAT5.

]]>